Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL237 and Serplulimab in Advanced Solid Tumors with PTEN Loss
NCT07446049Phase 2Not yet recruiting
- Sponsor
- Convalife Pharmaceutical
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of CVL237 in solid tumor (advanced stage), metastatic solid tumors, sponsored by Convalife Pharmaceutical. Planned start May 2026; status: not yet recruiting.
02
Drugs
CVL237
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT07446049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446049.